Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB14 plus pemetrexed and cisplatin/carboplatin vs placebo plus pemetrexed and cisplatin/carboplatin in EGFR-mutated non-squamous NSCLC after EGFR-TKI failure
CTR20250935Phase 3Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCTB14 in non-small cell lung cancer (NSCLC), sponsored by Sinocelltech Group Limited. Started Mar 2025; status: active.
02
Drugs
SCTB14
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250935.